Table 1.
Clinicopathologic characteristics of cases grouped by SOX2 expression
| Characteristic | SOX2 expression | Total (n = 75) | P value | |
|---|---|---|---|---|
|
| ||||
| Low (n = 35) | High (n = 40) | |||
| Age at diagnosis | ||||
| Mean ± SD | 57 ± 12 | 58 ± 12 | 57 ± 12 | 0.33 |
| Median (min; max) | 59 (37; 100) | 60 (32; 85) | 58 (32; 100) | |
| Gender (%) | ||||
| Female | 2 (6) | 1 (3) | 3 (4) | 0.91 |
| Male | 33 (94) | 39 (97) | 72 (96) | |
| Pre-operative CCRT (%) | ||||
| Yes | 27 (77) | 24 (60) | 51 (68) | 0.11 |
| No | 8 (23) | 16 (40) | 24 (32) | |
| Tumor grade (%) | ||||
| Grade 1 | 4 (11) | 1 (3) | 5 (7) | 0.51 |
| Grade 2 | 25 (72) | 29 (72) | 54 (72) | |
| Grade 3 | 6 (17) | 10 (25) | 16 (21) | |
| pT (%) | ||||
| pT1-2 | 12 (34) | 13 (33) | 25 (33) | 0.87 |
| pT3-4 | 23 (66) | 27 (67) | 50 (67) | |
| pN (%) | ||||
| pN0 | 20 (57) | 25 (63) | 45 (60) | 0.64 |
| pN1-3 | 15 (43) | 15 (37) | 30 (40) | |
| pM (%) | ||||
| pM0 | 32 (91) | 38 (95) | 70 (93) | 0.88 |
| pM1 | 3 (9) | 2 (5) | 5 (7) | |
| Pathologic stage (%) | ||||
| I/II | 20 (57) | 24 (60) | 44 (59) | 0.80 |
| III/IV | 15 (43) | 16 (40) | 31 (41) | |
| cT (%)a | ||||
| cT1-2 | 10 (32) | 15 (43) | 25 (38) | 0.38 |
| cT3-4 | 21 (68) | 20 (57) | 41 (62) | |
| cN (%)a | ||||
| cN0 | 6 (19) | 16 (50) | 22 (35) | 0.011 |
| cN1-3 | 25 (81) | 16 (50) | 41 (65) | |
| cM (%)a | ||||
| cM0 | 29 (97) | 26 (96) | 55 (96) | 1.0 |
| cM1 | 1 (3) | 1 (4) | 2 (4) | |
| Clinical stage (%)a | ||||
| I/II | 8 (35) | 13 (52) | 21 (44) | 0.23 |
| III/IV | 15 (65) | 12 (48) | 27 (56) | |
| Podoplanin expression (%) | ||||
| High | 20 (57) | 12 (30) | 32 (43) | 0.018 |
| Low | 15 (43) | 28 (70) | 43 (57) | |
SD: standard deviation; CCRT: concurrent chemoradiotherapy.
a
Some cases were excluded due to incomplete pre-treatment clinical staging.